Hologic, Inc. – NASDAQ:HOLX
Hologic stock price today
$67.62
-4.97
-6.86%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Hologic stock price monthly change
-6.55%
month
Hologic stock price quarterly change
-6.55%
quarter
Hologic stock price yearly change
+2.34%
year
Hologic key metrics
Market Cap | 16.29B |
Enterprise value | 21.06B |
P/E | 21.04 |
EV/Sales | 4.71 |
EV/EBITDA | 12.31 |
Price/Sales | 4.62 |
Price/Book | 4.05 |
PEG ratio | -0.72 |
EPS | 1.80 |
Revenue | 3.97B |
EBITDA | 1.16B |
Income | 438.5M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 22.17% |
Oper. margin | 28.27% |
Gross margin | 58.87% |
EBIT margin | 28.27% |
EBITDA margin | 29.36% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHologic stock price history
Hologic stock forecast
Hologic financial statements
Average Price Target
$87.33
Potential upside: 29.15%
Analysts Price target
Financials & Ratios estimates
| Apr 2023 | 1.02B | 218.5M | 21.29% |
|---|---|---|---|
| Jul 2023 | 984.4M | -40.5M | -4.11% |
| Sep 2023 | 945.3M | 90.6M | 9.58% |
| Mar 2024 | 1.01B | 169.9M | 16.69% |
| Apr 2023 | 9448700000 | 4.14B | 43.9% |
|---|---|---|---|
| Jul 2023 | 9337900000 | 4.15B | 44.51% |
| Sep 2023 | 9139300000 | 4.12B | 45.11% |
| Mar 2024 | 8714400000 | 3.87B | 44.41% |
| Apr 2023 | 206.3M | -16.4M | -49.5M |
|---|---|---|---|
| Jul 2023 | 332.8M | -38.7M | -109.6M |
| Sep 2023 | 258.7M | -56M | -210.6M |
| Mar 2024 | 292.4M | -38.5M | -4.2M |
Hologic alternative data
| Sep 2023 | 6,944 |
|---|---|
| Oct 2023 | 6,944 |
| Nov 2023 | 6,944 |
| Dec 2023 | 6,990 |
| Jan 2024 | 6,990 |
| Feb 2024 | 6,990 |
| Mar 2024 | 6,990 |
| Apr 2024 | 6,990 |
| May 2024 | 6,990 |
| Jun 2024 | 6,990 |
| Jul 2024 | 6,990 |
Hologic other data
94.17%
+3.41%
of HOLX is owned by hedge funds
667
-3
238.33M
+8.10M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 30957 |
| Mar 2024 | 0 | 26945 |
| Jul 2024 | 0 | 56750 |
| Aug 2024 | 0 | 58248 |
| Dec 2024 | 0 | 24856 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MITCHELL ESSEX D officer: Chief Operating Officer | Common Stock | 8,915 | $71.13 | $634,124 | ||
Option | MITCHELL ESSEX D officer: Chief Operating Officer | Common Stock | 7,505 | $68.35 | $512,967 | ||
Option | MITCHELL ESSEX D officer: Chief Operating Officer | Common Stock | 4,526 | $45.61 | $206,431 | ||
Option | MITCHELL ESSEX D officer: Chief Operating Officer | Common Stock | 1,956 | $40.97 | $80,137 | ||
Sale | MITCHELL ESSEX D officer: Chief Operating Officer | Common Stock | 24,856 | $76.34 | $1,897,482 | ||
Option | MITCHELL ESSEX D officer: Chief Operating Officer | Non-qualified Stock Option (Right to Buy) | 8,915 | $71.13 | $634,124 | ||
Option | MITCHELL ESSEX D officer: Chief Operating Officer | Non-qualified Stock Option (Right to Buy) | 13,987 | $51.64 | $722,331 | ||
Option | OBERTON KARLEEN MARIE officer: Chief Fi.. | Common Stock | 6,725 | $40.85 | $274,716 | ||
Option | OBERTON KARLEEN MARIE officer: Chief Fi.. | Common Stock | 26,080 | $40.97 | $1,068,498 | ||
Sale | OBERTON KARLEEN MARIE officer: Chief Fi.. | Common Stock | 52,679 | $80.56 | $4,243,662 |
| Patent |
|---|
Grant Filling date: 6 Jun 2019 Issue date: 27 Sep 2022 |
Grant Utility: System and method for targeted object enhancement to generate synthetic breast tissue images Filling date: 28 Mar 2018 Issue date: 20 Sep 2022 |
Grant Utility: Medical procedure draping system Filling date: 16 Aug 2018 Issue date: 13 Sep 2022 |
Grant Filling date: 25 Oct 2021 Issue date: 6 Sep 2022 |
Application Filling date: 20 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 17 Mar 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 24 May 2019 Issue date: 30 Aug 2022 |
Grant Filling date: 14 Feb 2020 Issue date: 23 Aug 2022 |
Grant Utility: Image quality compliance tool Filling date: 31 Jan 2020 Issue date: 23 Aug 2022 |
Application Filling date: 19 Jan 2022 Issue date: 18 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q2 2024 2 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 1 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 9 Nov 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 31 Jul 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Stephen P. MacMillan (1964) Chairman, Chief Executive Officer & Pres | $4,760,000 |
| Mr. Kevin R. Thornal (1974) Division Pres of Diagnostic Solutions | $1,880,000 |
| Ms. Karleen M. Oberton (1970) Chief Financial Officer | $1,450,000 |
| Mr. John M. Griffin (1961) Gen. Counsel | $1,380,000 |
Hologic: Soft Performance, But Cheap Enough
Hologic: Women's Health Play Looks Healthier Itself
Hologic: Prospects For Growth As Headwinds Disappear
Hologic: Navigating The Covid Cliff
InMode: Bullish Support Failed To Materialize
InMode: No Respect - Take Off Soon
Hologic: Additional Critical Factors Forming Bullish Thesis, Reiterate Buy
Zimmer Biomet: Profit Growth Superb, Q1 Knee Growth, But Further Evidence Needed
Hologic: A Superb Steward Of Capital, Offsets Top-Line Risks
-
What's the price of Hologic stock today?
One share of Hologic stock can currently be purchased for approximately $67.62.
-
When is Hologic's next earnings date?
Unfortunately, Hologic's (HOLX) next earnings date is currently unknown.
-
Does Hologic pay dividends?
No, Hologic does not pay dividends.
-
How much money does Hologic make?
Hologic has a market capitalization of 16.29B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 0% to 4.03B US dollars.
-
What is Hologic's stock symbol?
Hologic, Inc. is traded on the NASDAQ under the ticker symbol "HOLX".
-
What is Hologic's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Hologic?
Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Hologic's key executives?
Hologic's management team includes the following people:
- Mr. Stephen P. MacMillan Chairman, Chief Executive Officer & Pres(age: 61, pay: $4,760,000)
- Mr. Kevin R. Thornal Division Pres of Diagnostic Solutions(age: 51, pay: $1,880,000)
- Ms. Karleen M. Oberton Chief Financial Officer(age: 55, pay: $1,450,000)
- Mr. John M. Griffin Gen. Counsel(age: 64, pay: $1,380,000)
-
How many employees does Hologic have?
As Jul 2024, Hologic employs 6,990 workers.
-
When Hologic went public?
Hologic, Inc. is publicly traded company for more then 35 years since IPO on 1 Mar 1990.
-
What is Hologic's official website?
The official website for Hologic is hologic.com.
-
Where are Hologic's headquarters?
Hologic is headquartered at 250 Campus Drive, Marlborough, MA.
-
How can i contact Hologic?
Hologic's mailing address is 250 Campus Drive, Marlborough, MA and company can be reached via phone at +508 2632900.
-
What is Hologic stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Hologic in the last 12 months, the avarage price target is $87.33. The average price target represents a 29.15% change from the last price of $67.62.
Hologic company profile:
Hologic, Inc.
hologic.comExchange:
NASDAQ
Full time employees:
6,990
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
250 Campus Drive
Marlborough, MA 01752
Marlborough, MA 01752
CIK: 0000859737
ISIN: US4364401012
CUSIP: 436440101
